Alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis demonstrate durable slowing of brain volume loss over 5 years with most not receiving treatment for 4 years-CARE-MS I and II extension study

作者:Inshasi Jihad Said; Al Jumah Mohammed; Alroughani Raed; Compston D Alasdair S; Filippi Massimo; Giovannoni Gavin; Havrdova Eva; Yamout Bassem; Margolin David H; Thangavelu Karthinathan
来源:MENACTRIMS Congress, 2016-03-17 to 2016-03-19.
  • 出版日期2016-5